Innovation in Antibody-Drug Conjugates (ADCs)
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Drug Development".
Deadline for manuscript submissions: closed (31 December 2023) | Viewed by 18089
Special Issue Editors
Interests: ADC, tumor microenvironment, phase I, phase II, aggressive breast cancer, inflammatory breast cancer, triple-negative breast cancer
Special Issues, Collections and Topics in MDPI journals
2. McKetta Department of Chemical Engineering, The University of Texas at Austin, Austin, TX 78712, USA
Interests: biotechnology; protein therapeutics; vaccine development; applied immunology and microbiology
Special Issue Information
Dear Colleagues,
The recent approval by many regulatory boards of various Antibody-drug conjugates (ADC) had a dramatic improvement in the outcome of cancer patients. Since the first approval of ADC more than 20 years ago, there has been a major effort to improve its efficacy of ADC. This overall efficacy ADC is defined by antibody, linker, and payload. Further, these factors will impact the overall toxicities. This Special Issue of ADC allows us to present the latest research related to ADC and collectively show the future of ADC research direction. We are pleased to invite you to address the innovative approach to treating cancer by ADC, novel modification, and the translational and clinical impact of ADC in cancer management.
Prof. Dr. Naoto T. Ueno
Prof. Dr. Jennifer Maynard
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- antibody
- cancer
- linker
- payload
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
